美国Agennix
GPC Biotech AG (NASDAQ: GPCB) 和 Agennix 于2009年2月18号签订商业合并协议

Agennix AG is a biopharmaceutical company resulting from the combination of GPC Biotech AG and Agennix Incorporated in November 2009. We seek to have a meaningful impact on the length and quality of lives of cancer patients in areas of major unmet medical need by developing, and obtaining approval for, novel oncology therapies.

Our most advanced program is talactoferrin, an oral targeted therapy that is in Phase 3 clinical trials in non-small cell lung cancer. Additional clinical trials with talactoferrin in cancer indications are planned, including kidney cancer, for which Phase 2 data are available. Our other clinical development programs include RGB-286638, a multi-targeted kinase inhibitor in Phase 1 testing; the oral platinum-based compound satraplatin; and a topical gel form of talactoferrin for wound healing.

We are a transatlantic company with sites in Munich, Germany; Princeton, New Jersey and Houston, Texas.